Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic Variation in Sodium-glucose Cotransporter 2 and Heart Failure.

Clinical pharmacology and therapeutics - 1 Jul 2021

Katzmann Julius L, Mason Amy M, März Winfried, Kleber Marcus E, Niessner Alexander, Blüher Matthias, Speer Thimoteus, Laufs Ulrich

Abstract excerpt

Inhibition of sodium-glucose cotransporter 2 (SGLT2) represents an emerging pharmaceutical approach for the treatment of heart failure. The mechanisms by which SGLT2 inhibitors reduce the risk of heart failure are not well understood. The objective of this study was to investigate the association between single nucleotide polymorphisms (SNPs) in the SLC5A2 gene, encoding SGLT2, and heart failure, and to assess...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Coronary Artery Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Diabetes Mellitus, Type 2

Share to Genetic Variation

Share to Heart Disease Risk Factors

Share to Heart Failure

Share to Polymorphism, Single Nucleotide

Share to United Kingdom

Source

Identifiers

PMID: 33405238
DOI: 10.1002/cpt.2153

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic Variation in Sodium-glucose Cotransporter 2 and Heart Failure.PMID 33405238Read ↗

Genetic variation in solute carrier family 5 member 2 mimicking sodium-glucose co-transporter 2-inhibition and risk of cardiovascular disease and all-cause mortality: reduced risk not explained by lower plasma glucose.Semantic proximity Read ↗

Search for a Functional Genetic Variant Mimicking the Effect of SGLT2 Inhibitor Treatment.Semantic proximity Read ↗

Genetic Variants in SGLT1, Glucose Tolerance, and Cardiometabolic RiskSemantic proximity Read ↗

Mendelian randomization study of sodium-glucose cotransporter 2 inhibitors in cardiac and renal diseases.Semantic proximity Read ↗

Long-Term Efficacy and Safety of GLP-1R Agonist and SGLT2 Inhibitor Therapy in the General Population: A 2x2 Factorial Mendelian Randomization StudySemantic proximity Read ↗

SGLT2 inhibition, circulating metabolites, and atrial fibrillation: a Mendelian randomization study.Semantic proximity Read ↗

Sodium-glucose cotransporter 1 inhibition and gout: Mendelian randomisation study.Semantic proximity Read ↗

Genetic variation in sodium glucose co-transporter 1 and cardiac structure and function at middle age.Semantic proximity Read ↗

Effects of SGLT2 inhibition on incident heart failure in carriers of cardiomyopathy-associated genetic variants.Semantic proximity Read ↗

Genetic insights into SGLT2 inhibition and atrial fibrillation: exploring the mediating role of inflammatory proteins.Semantic proximity Read ↗

Are SGLT2 polymorphisms linked to diabetes mellitus and cardiovascular disease? Prospective study and meta-analysisSemantic proximity Read ↗

Efficacy and safety of SGLT2 inhibitors in the treatment of heart failure-May raise creatinine levels in patients: A meta-analysisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.